The World of GLP-1s

Past, Present and Future State of Weight Loss Prescribing

9:45 AM

May 1, 2025



Introductions

Speakers:

Peter Norton, MBA - Area Vice President, Pharmacy, AJ Gallagher

Nick Rabatic - Area Senior Vice President, AJ Gallagher

Moderator:

#iasboAC25

Brian O'Keeffe, Ed.D, SFO - Assistant Superintendent for Business Operations, Community Unit School District 200








PURSUING YOUR PURPOSE

CELEBRATING

YEARS

CONFERENCE

GLP-1s: A brief history



GLP-1 market update

Where things stand today

- Potential loss of 15-20% of body weight, DTC advertising and popular press coverage has added tremendous demand
- Payers are likely to face challenges regardless of what GLP-1 coverage strategy they choose due to high costs and high demand for these drugs
- Individuals continue to seek coverage for type 2 diabetes (T2D) GLP-1s and use the drugs off-label for weight loss
- An estimated 50% of self-funded employers are not covering GLP-1s for weight loss
- In 2023, non-healthcare organizations reported PMPM costs for GLP-1 medications ranging from \$16 to \$30 PMPM, respectively. For healthcare organizations, the high end of the range was approaching \$50 PMPM.



What do we know?

Average price tag of semaglutide is \$10,500 - \$12,500 per year per patient

Median duration on therapy is ~6 months

Relatively high **discontinuation** rates (due to adverse effects, nonadherence, etc.) up to 40% discontinue

therapy within **1 year**

Consideration of hospitalization and medical costs of **adverse** events

Influx of **point solutions** to

supplement lifestyle modifications, and care services for weight management

At this time, most fully-insured plans consider weight management a cosmetic exclusion, unless mandated by state law

PURSUING YOUR PURPOSE with

Do the outcomes justify the costs and potential risks?

#iasboAC25

- Majority of ICER panelists found semaglutide combined with lifestyle modifications represents "low" long-term value for money overall and "low" long-term value for money compared to legacy products (i.e. Qsymia)
- Estimated lifetime cost is ~\$274k for Wegovy, with an offset to medical cost of ~\$62k for a net lifetime cost of ~\$213k
- Prime Therapeutics conducted a 2-year analysis which found "no reduction in obesity-related medical events," such as heart attacks, strokes and diagnoses of type 2 diabetes, or use of prescription drugs for hypertension and high cholesterol compared to the control group



YEARS

GLP-1 products today



PURSUING YOUR PURPOSE with



The good...

- Highly effective
- Tolerable side effects
- High media attention
- Positive impact to other related chronic conditions •

The bad...

#iasboAC25

- Costly drug
- High consumer demand
- Some not approved for obesity
- High off-label use impacting supply issues
- When drug is stopped, weight is re-gained unless lifestyle changes occur

	Saxenda	Ozempic	Wegovy	Mounjaro	Zepbound
Active Ingredient	liraglutide	semaglutide	semaglutide	tirzepatide	tirzepatide
Route	Self- Administere d injection	Self- Administered injection	Self- Administered injection	Self- Administered injection	Self- Administere d injection
Dose Timing	Daily	Weekly	Weekly	Weekly	Weekly
FDA Approval	Obesity	Type II Diabetes	Obesity	Type II Diabetes	Obesity
Mean % weight loss	5.4% - 7.4%	5-10%	9.6% - 16%	Up to 20%	Up to 20%





Estimated cost for coverage of weight loss drugs

Sample employer

#iasboAC25

Prevalence and Membership						
Prevalence of Obesity in U.S. (2021) ¹	42%					
Client ABC - Current Member Count	9,000					
Client ABC - Est Usage Based on US Obesity						
Prevalence	3,780					
Est. Annual Cost of Wegovy	\$10,000					
Estimated An	nual Costs ^{2,3}					
2% members seek treatment	\$1,800,000	\$16.67 PMPM				
4% members seek treatment	\$3,600,000	\$33.33 PMPM				
5% members seek treatment	\$4,500,000	\$41.67 PMPM				
10% members seek treatment	\$9,000,000	\$83.33 PMPM				

PURSUING YOUR PURPOSE

1. https://www.cdc.gov/obesity/data/prevalence-maps.html. Accessed 04/10/23

2. Estimated gross cost includes member costs but nets out rebates, assumes 8 scripts (30 days supply) filled per year.

3. Based on national estimated prevalence of obesity, Client ABC current population size and 8 scripts (30 days scripts) per year per member, assuming partial adherence





CELEBRATING

Drug pipeline for weight loss

More new products on the horizon

Drug Name	Manufacturer	Dosing Frequency	Route	Status
Oral semaglutide	Novo Nordisk	Once daily	Oral	Phase 3; 2024
CagriSema	Novo Nordisk	Once weekly	SQ	Phase 3; 2026
Orforglipron	Eli Lilly	Once daily	Oral	Phase 3; 2026+
Retatrutide	Eli Lilly	Once weekly	SQ	Phase 3; 2027

- This chart notes weight loss drugs that are pending approval or in Phase 3. The pipeline is robust with multiple weight loss drugs in phase 2 trials as well
- Some of these drugs are also seeking other indications for Type 2 diabetes mellitus and non-alcoholic steatohepatitis (NASH)
- Currently weight loss medications are not commonly used in the pediatric population. With the new American Academy of Pediatrics (AAP) guidelines and recent label expansions of the GLP-1 RAs for weight loss, utilization in this population is anticipated to increase.



GLP-1s: Beyond diabetes and weight loss

Pipeline for new products and indications

1Q 2025	2Q 2025	3Q 2025	4Q 2025	2026+
 Zepbound for OSA* Ozempic for CKD + diabetes Rybelsus (semegulatide) - 1st oral weight loss agent 	Zepbound for Heart Failure	 Wegovy for Heart Failure Orforglipron – new oral weight loss agent Wegovy for MASH 	 No anticipated FDA approvals 	 Alzeheimer's Disease approvals New agents and mechanisms: CagriSema, Retatrutide, Survodutide
*Approval received December 20 CKD = Chronic Kidney Disease MASH = metabolic dysfunction-ass OSA = obstructive sleep apnea), 2024 sociated steatohepatitis (fatty liver dise	ase)		

PURSUING YOUR PURPOSE



GALLAGHER



CELEBRATING

Weight management vendors Potential partners

- GLP-1s for weight loss pose the issue of how to keep members engaged and motivated to change behavior when they don't have the "stick" of a Type-2 diabetic diagnosis
- Pharmacy Benefit Manager (PBM) programs like Express Scripts' EncircleRx have a third-party weight management element included, which makes up much of the cost of the program
- Outside of PBM programs, several vendors have emerged as partners to health plans/plan sponsors as solutions to engage membership and encourage GLP-1 patients to adopt and maintain healthier lifestyles, which maximizes the value of the medication
- PBMs are beginning to enforce fees and potential rebate impacts for clients that enlist these 3rd party solutions



Key considerations for plan sponsors

5 6

#iasboAC25

Plan elections regarding coverage of weight loss*

Review/understand PBM's Prior Authorization criteria relative to competitors

Additional new products and indications on the horizon

Explore third party vendors for utilization management and weight management

Adherence monitoring and possible novel payment solutions

Review of medical data to identify and address off-label use for diabetic indications

*An estimated 50% of commercial plan sponsors are currently excluding weight loss medications from coverage



PURSUING YOUR PURPOSE with





Questions and Answers

We thank you for your time!



Presenters:

MODERATOR INFO:

Brian K. O'Keeffe, Ed.D., SFO, Assistant Superintendent for Business Operations Community Unit School District 200 (630) 682-2025; brian.okeeffe@cusd200.org

PANELISTS INFO:

Peter Norton, Area Vice President, Pharmacy; AJ Gallagher (201) 571-3845; peter_norton@ajg.com

Nick Rabatic, Area Senior Vice President; AJ Gallagher (847) 713-6527 ; nick_rabatic@ajg.com

CELEBRATING

